New drug DT-109 reverses severe fatty liver disease in animals by repairing the gut barrier
An experimental tripeptide, DT-109, reversed MASH in animal models by curbing harmful gut bacteria and sealing the intestinal barrier that protects the liver.
Summary
Metabolic dysfunction-associated steatohepatitis (MASH) is a severe form of fatty liver disease affecting roughly 7% of people worldwide. It can progress to cirrhosis, liver cancer and liver failure, and treatment options remain limited. University of Michigan researchers report that an experimental compound called DT-109, a three-amino-acid peptide built on glycine, reversed MASH in animal models. Rather than acting on the liver alone, it works through the gut. The drug reduced overgrowth of Clostridium perfringens, a bacterium that produces ammonia and damages the intestinal lining. By protecting that barrier, DT-109 blocked microbial toxins from reaching the liver, where they trigger inflammation and overactivate CD8+ T cells. The work, published in The Journal of Clinical Investigation, points to the gut-liver axis as a treatment target and may have implications for cardiovascular disease. The results come from animal studies, so human benefit remains unproven.
Detailed Summary
Fatty liver disease is among the most common metabolic conditions of midlife and later life, and its severe form, metabolic dysfunction-associated steatohepatitis (MASH), affects roughly 7% of the global population. In MASH, excess liver fat drives inflammation and cell damage, and over time it can lead to cirrhosis, liver cancer and liver failure. Although treatments have improved recently, effective options are still limited, which is why new mechanisms matter.
Researchers at Michigan Medicine report that DT-109, a glycine-based tripeptide, reversed MASH in animal models. The same team had shown earlier that the compound improved MASH, but the mechanism was unclear. The new study, published in The Journal of Clinical Investigation, points to the gut as the key site of action.
The scientists first confirmed that overgrowth of Clostridium perfringens, a bacterium that produces ammonia in the intestine, contributes to MASH. Rising ammonia damages the intestinal lining. As that barrier weakens, microbial toxins and other products leak toward the liver, provoking inflammation and excessive activation of CD8+ T cells, immune cells that become harmful when overactive. DT-109 interrupted this chain by reducing harmful bacteria, protecting the gut epithelial barrier and limiting the influx of inflammatory microbial products.
The findings strengthen the case for the gut-liver axis as a therapeutic target. They may also bear on other conditions linked to gut barrier dysfunction, including cardiovascular disease, according to the researchers. For readers, the study reinforces that intestinal health and metabolic liver health are connected, though it does not yet translate into any actionable treatment or supplement.
The main caveat is that all the evidence comes from animal models. DT-109 is experimental, and its safety, dosing and effectiveness in humans are untested. Animal MASH models do not fully reproduce the human disease, and the news summary leaves out details such as sample sizes and effect magnitudes. Human trials will be needed before conclusions about clinical benefit can be drawn.
Key Findings
- DT-109, a glycine-based tripeptide, reversed severe fatty liver disease (MASH) in animal models.
- Overgrowth of ammonia-producing Clostridium perfringens contributes to gut barrier damage in MASH.
- DT-109 reduced harmful gut bacteria and protected the intestinal lining, limiting toxin flow to the liver.
- Leaked microbial products drive liver inflammation and overactivation of CD8+ T cells.
- Results are preclinical; human safety and efficacy of DT-109 have not been shown.
Methodology
This is a university press-release summary on ScienceDaily describing a preclinical study in The Journal of Clinical Investigation, a reputable peer-reviewed journal. The evidence comes from animal models, and the article gives no quantitative data.
Study Limitations
Findings come from animal models, which may not predict human outcomes, and the press summary omits sample sizes, doses and effect sizes. The article text was truncated, so some of the cardiovascular implications are not fully described. Check the original Journal of Clinical Investigation paper for methods, safety data and the strength of the evidence.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: